Government-Owned Inventions; Availability for Licensing, 43455-43456 [E8-17031]

Download as PDF Federal Register / Vol. 73, No. 144 / Friday, July 25, 2008 / Notices biomarkers for radiation gamma exposure and cell damage. Please contact John D. Hewes, PhD, at 301– 435–3121 or hewesj@mail.nih.gov for more information. Dated: July 17, 2008. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E8–17021 Filed 7–24–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: mstockstill on PROD1PC66 with NOTICES SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Prolactin Receptor Antibodies as a Diagnostic Marker and Therapeutic Agent for Cancer Description of Technology: Prolactin is a key hormone in the normal breast development and plays a role in the growth and development of other major organs such as the prostate. The biologic function of prolactin is mediated by specific receptors on the cell surface, with breast cancer cells containing more receptors than normal tissue. The prolactin receptor, a member of the large class-1 cytokine receptor superfamily, has three major isoforms that are cell associated. The specific isoform concentration and distribution determines biological activity and may VerDate Aug<31>2005 17:15 Jul 24, 2008 Jkt 214001 determine susceptibility to antiprolactin drugs. This technology describes several antibodies, both polyclonal and monoclonal, to the prolactin receptor. These include antibodies to the three major isoforms: the long isoform (LF), two short isoforms (SF1a and SF1b), and the secreted form, prolactin receptor D7–11. These antibodies can be used for the diagnosis of prolactin sensitive tumors. Furthermore, the presence of the secreted prolactin receptor D7–11 may provide a blood test for prolactin responsive tumors. Applications: • Diagnostic tool for the detection of prolactin sensitive tumors. • Antibodies as a serum diagnostic in high-throughput assays. • Conjugated antibodies used in targeted therapy of cancer. Market: • In the U.S. over 2 million women have been treated for breast cancer and with more than 200,000 women diagnosed in the year 2007 alone. Breast cancer is the second leading cause of cancer death in women. • Prostate cancer is the most common type of cancer found in American men, and it has been estimated that there were more than 230,000 new cases in the U.S. in 2007. Prostate cancer is also the second leading cause of cancer death in men. Development Status: The technology is currently in the pre-clinical stage of development. Inventors: Barbara Vonderhaar, Erika Ginsburg, Paul Goldsmith (NCI). Patent Status: HHS Reference No. E– 232–2008/0—Research Material. Patent protection is not being pursued for this technology. Licensing Status: Available for licensing. Licensing Contact: Whitney A. Hastings; 301–451–7337; hastingw@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute, Mammary Biology and Tumorigenesis Laboratory is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize isoform specific antibodies to the human prolactin receptor. Please contact John D. Hewes, PhD, at 301–435–3121 or hewesj@mail.nih.gov for more information. Mouse Embryonic Stem Cell-Based Functional Assay To Evaluate Mutations in BRCA2 Description of Technology: Mutations in breast cancer susceptibility genes PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 43455 BRCA1 and BRCA2 have up to an 80% life time risk in developing breast cancer. There are no ‘‘mutation hot spots’’ and to date, more than 1,500 different mutations have been identified in BRCA2. The absence of tumor cell lines expressing various mutant BRCA2 alleles has hindered evaluations to determine the functional differences between different mutations. A simple, versatile and reliable mouse embryonic stem cell and bacterial artificial chromosome based assay to generate cell lines expressing mutant human BRCA2 has been developed and it has been used to classify 17 sequence variants. Available for licensing are a wild-type and eleven mutant BRCA2 cell lines developed from this assay that have either truncations or point mutations. These cell lines may be used to evaluate the effect of DNA damaging agents, genotoxins and chemotherapeutic efficacy. Applications: • Research tool to generate and study BRCA2 mutations. • Method to screen for chemotherapeutics. • Method to evaluate DNA damaging agents. Advantages: Ready to use portfolio of BRCA2 mutant cell lines to study BRCA2 mutant functional analysis. Market: An estimated 180,510 new cases of breast cancer will be diagnosed and may cause 40,480 deaths in the U.S. in 2008. Inventors: Shyam K. Sharan and Sergey Kuznetsov (NCI). Publication: SG Kuznetsov et al. Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2. Nat Med. 2008, in press. Published online 11 July 2008, doi:10.1038/nm.1719. Patent Status: HHS Reference No. E– 261–2007/0—Research Tool. Patent protection is not being pursued for this technology. Licensing Status: Available for biological materials licensing only. Licensing Contact: Jennifer Wong; (301) 435–4633; wongje@mail.nih.gov. Collaborative Research Opportunity: The Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize mouse embryonic stem cell lines suitable for functional analysis of BRCA2 variants. Please contact John D. Hewes, PhD, at 301–435–3121 or hewesj@mail.nih.gov for more information. E:\FR\FM\25JYN1.SGM 25JYN1 43456 Federal Register / Vol. 73, No. 144 / Friday, July 25, 2008 / Notices Dated: July 17, 2008. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E8–17031 Filed 7–24–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Notice of Closed Meetings mstockstill on PROD1PC66 with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Mental Health Special Emphasis Panel; ITMA/ITSP Conflicts. Date: July 28, 2008. Time: 12:30 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Christopher S. Sarampote, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6148, MSC 9608, Bethesda, MD 20892, 301–443–1959, csarampo@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Mental Health Special Emphasis Panel; Summer AIDS T32s. Date: July 31, 2008. Time: 1 p.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Henry J Haigler, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Rm. 6150, MSC 9608, VerDate Aug<31>2005 17:15 Jul 24, 2008 Jkt 214001 Bethesda, MD 20892–9608, 301/443–7216, hhaigler@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Mental Health Special Emphasis Panel; AIDS Center Supplement. Date: August 4, 2008. Time: 1 p.m. to 2:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Henry J. Haigler, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Rm. 6150, MSC 9608, Bethesda, MD 20892–9608, 301/443–7216, hhaigler@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS) Dated: July 18, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–17033 Filed 7–24–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; K99 Member Conflict. Date: August 7, 2008. Time: 11 a.m. to 1 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Joann McConnell, PhD, Scientific Review Administrator, Scientific Review Branch, NIH/NINDS/Neuroscience Center, 6001 Executive Blvd., Suite 3208, Msc 9529, Bethesda, MD 20892–9529, (301) 496–5324, mcconnej@ninds.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; R25 Review Panel. Date: August 12, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: The Westin Embassy Row, Washington, DC, 2100 Massachusetts Avenue, NW., Washington, DC 20008. Contact Person: Phillip F. Wiethorn, Scientific Review Administrator, DHHS/NIH/ NINDS/DER/SRB, 6001 Executive Boulevard; Msc 9529, Neuroscience Center; Room 3203, Bethesda, MD 20892–9529, (301) 496–5388, wiethorp@ninds.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Epilepsy Clinical Trial. Date: August 22, 2008. Time: 9 a.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: William C. Benzing, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS/Neuroscience Center, 6001 Executive Boulevard, Suite 3204, Msc 9529, Bethesda, MD 20892, (301) 496–0660, benzingw@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated: July 18, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–17053 Filed 7–24–08; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\25JYN1.SGM 25JYN1

Agencies

[Federal Register Volume 73, Number 144 (Friday, July 25, 2008)]
[Notices]
[Pages 43455-43456]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-17031]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Prolactin Receptor Antibodies as a Diagnostic Marker and Therapeutic 
Agent for Cancer

    Description of Technology: Prolactin is a key hormone in the normal 
breast development and plays a role in the growth and development of 
other major organs such as the prostate. The biologic function of 
prolactin is mediated by specific receptors on the cell surface, with 
breast cancer cells containing more receptors than normal tissue. The 
prolactin receptor, a member of the large class-1 cytokine receptor 
superfamily, has three major isoforms that are cell associated. The 
specific isoform concentration and distribution determines biological 
activity and may determine susceptibility to antiprolactin drugs.
    This technology describes several antibodies, both polyclonal and 
monoclonal, to the prolactin receptor. These include antibodies to the 
three major isoforms: the long isoform (LF), two short isoforms (SF1a 
and SF1b), and the secreted form, prolactin receptor [Delta]7-11. These 
antibodies can be used for the diagnosis of prolactin sensitive tumors. 
Furthermore, the presence of the secreted prolactin receptor [Delta]7-
11 may provide a blood test for prolactin responsive tumors.
    Applications:
     Diagnostic tool for the detection of prolactin sensitive 
tumors.
     Antibodies as a serum diagnostic in high-throughput 
assays.
     Conjugated antibodies used in targeted therapy of cancer.
    Market:
     In the U.S. over 2 million women have been treated for 
breast cancer and with more than 200,000 women diagnosed in the year 
2007 alone. Breast cancer is the second leading cause of cancer death 
in women.
     Prostate cancer is the most common type of cancer found in 
American men, and it has been estimated that there were more than 
230,000 new cases in the U.S. in 2007. Prostate cancer is also the 
second leading cause of cancer death in men.
    Development Status: The technology is currently in the pre-clinical 
stage of development.
    Inventors: Barbara Vonderhaar, Erika Ginsburg, Paul Goldsmith 
(NCI).
    Patent Status: HHS Reference No. E-232-2008/0--Research Material. 
Patent protection is not being pursued for this technology.
    Licensing Status: Available for licensing.
    Licensing Contact: Whitney A. Hastings; 301-451-7337; 
hastingw@mail.nih.gov.
    Collaborative Research Opportunity: The National Cancer Institute, 
Mammary Biology and Tumorigenesis Laboratory is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate, or commercialize isoform 
specific antibodies to the human prolactin receptor. Please contact 
John D. Hewes, PhD, at 301-435-3121 or hewesj@mail.nih.gov for more 
information.

Mouse Embryonic Stem Cell-Based Functional Assay To Evaluate Mutations 
in BRCA2

    Description of Technology: Mutations in breast cancer 
susceptibility genes BRCA1 and BRCA2 have up to an 80% life time risk 
in developing breast cancer. There are no ``mutation hot spots'' and to 
date, more than 1,500 different mutations have been identified in 
BRCA2. The absence of tumor cell lines expressing various mutant BRCA2 
alleles has hindered evaluations to determine the functional 
differences between different mutations.
    A simple, versatile and reliable mouse embryonic stem cell and 
bacterial artificial chromosome based assay to generate cell lines 
expressing mutant human BRCA2 has been developed and it has been used 
to classify 17 sequence variants. Available for licensing are a wild-
type and eleven mutant BRCA2 cell lines developed from this assay that 
have either truncations or point mutations. These cell lines may be 
used to evaluate the effect of DNA damaging agents, genotoxins and 
chemotherapeutic efficacy.
    Applications:
     Research tool to generate and study BRCA2 mutations.
     Method to screen for chemotherapeutics.
     Method to evaluate DNA damaging agents.
    Advantages: Ready to use portfolio of BRCA2 mutant cell lines to 
study BRCA2 mutant functional analysis.
    Market: An estimated 180,510 new cases of breast cancer will be 
diagnosed and may cause 40,480 deaths in the U.S. in 2008.
    Inventors: Shyam K. Sharan and Sergey Kuznetsov (NCI).
    Publication: SG Kuznetsov et al. Mouse embryonic stem cell-based 
functional assay to evaluate mutations in BRCA2. Nat Med. 2008, in 
press. Published online 11 July 2008, doi:10.1038/nm.1719.
    Patent Status: HHS Reference No. E-261-2007/0--Research Tool. 
Patent protection is not being pursued for this technology.
    Licensing Status: Available for biological materials licensing 
only.
    Licensing Contact: Jennifer Wong; (301) 435-4633; 
wongje@mail.nih.gov.
    Collaborative Research Opportunity: The Mouse Cancer Genetics 
Program, Center for Cancer Research, National Cancer Institute, is 
seeking statements of capability or interest from parties interested in 
collaborative research to further develop, evaluate, or commercialize 
mouse embryonic stem cell lines suitable for functional analysis of 
BRCA2 variants. Please contact John D. Hewes, PhD, at 301-435-3121 or 
hewesj@mail.nih.gov for more information.


[[Page 43456]]


    Dated: July 17, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E8-17031 Filed 7-24-08; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.